Cargando…
Synergistic Network Pharmacology for Traditional Chinese Medicine Liangxue Tongyu Formula in Acute Intracerebral Hemorrhagic Stroke
BACKGROUND: Nowadays, acute intracerebral hemorrhage stroke (AICH) still causes higher mortality. Liangxue Tongyu Formula (LXTYF), originating from a traditional Chinese medicine (TCM) prescription, is widely used as auxiliary treatment for AICH. OBJECTIVE: To dig into the multicomponent, multitarge...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936909/ https://www.ncbi.nlm.nih.gov/pubmed/33727915 http://dx.doi.org/10.1155/2021/8874296 |
_version_ | 1783661286367690752 |
---|---|
author | Chen, Yang Dong, Ju Yang, Dongqing Qian, Qin Wang, Pengcheng Yang, Xiaojuan Li, Wei Li, Guochun Shen, Xu Wang, Fushun |
author_facet | Chen, Yang Dong, Ju Yang, Dongqing Qian, Qin Wang, Pengcheng Yang, Xiaojuan Li, Wei Li, Guochun Shen, Xu Wang, Fushun |
author_sort | Chen, Yang |
collection | PubMed |
description | BACKGROUND: Nowadays, acute intracerebral hemorrhage stroke (AICH) still causes higher mortality. Liangxue Tongyu Formula (LXTYF), originating from a traditional Chinese medicine (TCM) prescription, is widely used as auxiliary treatment for AICH. OBJECTIVE: To dig into the multicomponent, multitarget, and multipathway mechanism of LXTYF on treating AICH via network pharmacology and RNA-seq. METHODS: Network pharmacology analysis was used by ingredient collection, target exploration and prediction, network construction, and Gene Ontology (GO) and KEGG analysis, with the Cytoscape software and ClusterProfiler package in R. The RNA-seq data of the AICH-rats were analyzed for differential expression and functional enrichments. Herb-Compound-Target-Pathway (H-C-T-P) network was shown to clarify the mechanism of LXTYF for AICH. RESULTS: 76 active ingredients (quercetin, Alanine, kaempferol, etc.) of LXTYF and 376 putative targets to alleviate AICH (PTGS2, PTGS1, ESR1, etc.) were successfully identified. The protein-protein interaction (PPI) network indicated the important role of STAT3. The functional enrichment of GO and KEGG pathway showed that LXTYF is most likely to influence MAPK and PI3K-Akt signaling pathways for AICH treatment. From the RNA-seq of AICH-rats, 583 differential mRNAs were identified and 14 of them were consistent with the putative targets of LXTYF for AICH treatment. The KEGG pathway enrichment also implied that the MAPK signaling pathway was the most correlated one among all the related signaling pathways. Many important targets with expression changes of LXTYF for AICH treatment and their related pathways are great markers of antioxidation, anti-inflammatory, antiapoptosis, and lowering blood pressure, which indicated that LXTYF may play mutiroles in the mechanisms for AICH treatment. CONCLUSION: The LXTYF attenuates AICH partially by antioxidation, anti-inflammatory, and antiapoptosis and lowers blood pressure roles through regulating the targets involved MAPK, calcium, apoptosis, and TNF signaling pathway, which provide notable clues for further experimental validation. |
format | Online Article Text |
id | pubmed-7936909 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-79369092021-03-15 Synergistic Network Pharmacology for Traditional Chinese Medicine Liangxue Tongyu Formula in Acute Intracerebral Hemorrhagic Stroke Chen, Yang Dong, Ju Yang, Dongqing Qian, Qin Wang, Pengcheng Yang, Xiaojuan Li, Wei Li, Guochun Shen, Xu Wang, Fushun Neural Plast Research Article BACKGROUND: Nowadays, acute intracerebral hemorrhage stroke (AICH) still causes higher mortality. Liangxue Tongyu Formula (LXTYF), originating from a traditional Chinese medicine (TCM) prescription, is widely used as auxiliary treatment for AICH. OBJECTIVE: To dig into the multicomponent, multitarget, and multipathway mechanism of LXTYF on treating AICH via network pharmacology and RNA-seq. METHODS: Network pharmacology analysis was used by ingredient collection, target exploration and prediction, network construction, and Gene Ontology (GO) and KEGG analysis, with the Cytoscape software and ClusterProfiler package in R. The RNA-seq data of the AICH-rats were analyzed for differential expression and functional enrichments. Herb-Compound-Target-Pathway (H-C-T-P) network was shown to clarify the mechanism of LXTYF for AICH. RESULTS: 76 active ingredients (quercetin, Alanine, kaempferol, etc.) of LXTYF and 376 putative targets to alleviate AICH (PTGS2, PTGS1, ESR1, etc.) were successfully identified. The protein-protein interaction (PPI) network indicated the important role of STAT3. The functional enrichment of GO and KEGG pathway showed that LXTYF is most likely to influence MAPK and PI3K-Akt signaling pathways for AICH treatment. From the RNA-seq of AICH-rats, 583 differential mRNAs were identified and 14 of them were consistent with the putative targets of LXTYF for AICH treatment. The KEGG pathway enrichment also implied that the MAPK signaling pathway was the most correlated one among all the related signaling pathways. Many important targets with expression changes of LXTYF for AICH treatment and their related pathways are great markers of antioxidation, anti-inflammatory, antiapoptosis, and lowering blood pressure, which indicated that LXTYF may play mutiroles in the mechanisms for AICH treatment. CONCLUSION: The LXTYF attenuates AICH partially by antioxidation, anti-inflammatory, and antiapoptosis and lowers blood pressure roles through regulating the targets involved MAPK, calcium, apoptosis, and TNF signaling pathway, which provide notable clues for further experimental validation. Hindawi 2021-02-26 /pmc/articles/PMC7936909/ /pubmed/33727915 http://dx.doi.org/10.1155/2021/8874296 Text en Copyright © 2021 Yang Chen et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Chen, Yang Dong, Ju Yang, Dongqing Qian, Qin Wang, Pengcheng Yang, Xiaojuan Li, Wei Li, Guochun Shen, Xu Wang, Fushun Synergistic Network Pharmacology for Traditional Chinese Medicine Liangxue Tongyu Formula in Acute Intracerebral Hemorrhagic Stroke |
title | Synergistic Network Pharmacology for Traditional Chinese Medicine Liangxue Tongyu Formula in Acute Intracerebral Hemorrhagic Stroke |
title_full | Synergistic Network Pharmacology for Traditional Chinese Medicine Liangxue Tongyu Formula in Acute Intracerebral Hemorrhagic Stroke |
title_fullStr | Synergistic Network Pharmacology for Traditional Chinese Medicine Liangxue Tongyu Formula in Acute Intracerebral Hemorrhagic Stroke |
title_full_unstemmed | Synergistic Network Pharmacology for Traditional Chinese Medicine Liangxue Tongyu Formula in Acute Intracerebral Hemorrhagic Stroke |
title_short | Synergistic Network Pharmacology for Traditional Chinese Medicine Liangxue Tongyu Formula in Acute Intracerebral Hemorrhagic Stroke |
title_sort | synergistic network pharmacology for traditional chinese medicine liangxue tongyu formula in acute intracerebral hemorrhagic stroke |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936909/ https://www.ncbi.nlm.nih.gov/pubmed/33727915 http://dx.doi.org/10.1155/2021/8874296 |
work_keys_str_mv | AT chenyang synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke AT dongju synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke AT yangdongqing synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke AT qianqin synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke AT wangpengcheng synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke AT yangxiaojuan synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke AT liwei synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke AT liguochun synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke AT shenxu synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke AT wangfushun synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke |